Beaumont Health

About: Beaumont Health is a nonprofit organization based out in Royal Oak, Michigan, United States. It is known for research contribution in the topics: Medicine & Population. The organization has 1483 authors who have published 1448 publications receiving 15407 citations. The organization is also known as: William Beaumont Health System & Beaumont Hospitals.

SPIN: Development of Sample-specific Protein Integrity Numbers as an Index of Biospecimen Quality

Abstract: It is widely accepted that variable biorepository specimen handling conditions can significantly alter outcomes of clinical research studies, suggesting the need for a metric for sample analyte pro...

Cultivating the Cyberinfrastructure Workforce via an Intermediate/Advanced Virtual Residency Workshop

Abstract: Cyberinfrastructure (CI) Facilitation is the process of helping researchers to use research computing systems and services to advance their computing-intensive/data-intensive research goals. The growing need for CI Facilitation isn't being met by traditional academic degree and certificate programs, so informal education is required. The Virtual Residency (VR) is a program that teaches key CI Facilitation skills to CI Facilitators. Using a combination of (a) workshops, (b) biweekly conference calls, (c) a Grant Proposal Writing Apprenticeship and (d) a new Paper Writing Apprenticeship, the VR has been teaching CI Facilitation since 2015. During the summers of 2015-17, the annual VR workshop was at an introductory level, driving demand for a higher level workshop. In 2018, the VR workshop was presented at a level described as intermediate, but in practice it included a great deal of advanced content, concentrated on institutional CI leadership. The 2018 focus areas were: (1) in-depth CI expertise in areas of rapidly changing technology; (2) CI leadership; (3) funding acquisition skills; (4) outreach strategies, techniques, and skills; (5) communication skills. The 2018 VR workshop served 216 participants from 147 institutions in 42 US states and 2 US territories plus 2 other countries.

Relation of Exercise Heart Rate Recovery to Predict Cardiometabolic Syndrome in Men.

Abstract: We examined the hypothesis that delayed heart rate recovery (HRR) after exercise testing, an estimate of decreased autonomic function, predicts the risk of cardiometabolic syndrome (MetS) and is associated with continuous MetS risk scores in healthy men. Participants were 2,740 men who underwent general health examinations and had no evidence of MetS, cardiovascular diseases, diabetes, and hypertension at baseline. Baseline HRR was calculated as the difference between peak heart rate attained during exercise testing and the heart rate at 1 (HRR 1) and 2 minutes (HRR 2) after test termination. Incident MetS was defined as participants having ≥3 MetS components, and continuous MetS risk score was computed as the sum of z-score of 5 risk factors at follow-up. The incidence of MetS was 61/1,000 person-years during an average follow-up of 5 years. The relative risks and 95% confidence interval (CI) of incident MetS in the lowest quartiles of HRR 1 and HRR 2 versus the highest quartile were 1.24 (95% CI 1.02 to 1.51) and 2.02 (95% CI 1.58 to 2.60), respectively, after adjusting for potential confounders, including peak oxygen uptake and resting heart rate. HRR 1 (s = −0.052, p = 0.005) and HRR 2 (s = −0.058, p = 0.009) were independently associated with clustered MetS risk scores after adjusting for covariates. In conclusion, the independent association between delayed HRR after exercise testing and incident MetS and continuous MetS risk scores suggests that decreased autonomic function may be considered as a parameter to predict the future likelihood of MetS.

Magnetic resonance imaging-guided transurethral ultrasound ablation in patients with localised prostate cancer: 3-year outcomes of a prospective Phase I study

Abstract: OBJECTIVES To report the 3-year follow-up of a Phase I study of magnetic resonance imaging (MRI)-guided transurethral ultrasound ablation (TULSA) in 30 men with localised prostate cancer. Favourable 12-month safety and ablation precision were previously described. PATIENTS AND METHODS As a mandated safety criterion, TULSA was delivered as near whole-gland ablation, applying 3-mm margins sparing 10% of peripheral prostate tissue in 30 men. After 12-month biopsy and MRI, biannual follow-up included prostate-specific antigen (PSA), adverse events (AEs), and functional quality-of-life assessment, with repeat systematic biopsy at 3 years. RESULTS A 3-year follow-up was completed by 22 patients. Between 1 and 3 years, there were no new serious or severe AEs. Urinary and bowel function remained stable. Erectile function recovered by 1 year and was stable at 3 years. The PSA level decreased 95% to a median (interquartile range) nadir of 0.33 (0.1-0.4) ng/mL, stable to 0.8 (0.4-1.6) ng/mL at 3 years. Serial biopsies identified clinically significant disease in 10/29 men (34%) and any cancer in 17/29 (59%). By 3 years, seven men had recurrence (four histological, three biochemical) and had undergone salvage therapy without complications (including six prostatectomies). At 3 years, three of 22 men refused biopsy, and two of the 22 (9%) had clinically significant disease (one new, one persistent). Predictors of salvage therapy requirement included less extensive ablation coverage and higher PSA nadir. CONCLUSION With 3-year Phase I follow-up, TULSA demonstrates safe and precise ablation for men with localised prostate cancer, providing predictable PSA and biopsy outcomes, without affecting functional abilities or precluding salvage therapy.

Efficacy of cabozantinib in advanced MiT family translocation renal cell carcinomas (TRCC).

Abstract: 274Background: MiT family translocation renal cell carcinomas (TRCC) represent a rare and aggressive subgroup of RCC harboring high expression of c-MET. While response rates of VEGF receptor-tyrosi...